SLC5A2 and type 2 diabetes mellitus: We look forward with optimism to the results of the following studies: The first, Mechanisms and Safety of SGLT2 Inhibition in Peritoneal Dialysis (CANARY study) [NCT05715814], is an open-label single-center study that will include 20 patients with and without T2DM who are on PD and have RKF, defined as a diuresis of at least 250 mL/24 h and a minimum GFR of 2 mL/min/1.73 m2.